[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR067701A1 - Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2 - Google Patents

Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2

Info

Publication number
AR067701A1
AR067701A1 ARP080103246A ARP080103246A AR067701A1 AR 067701 A1 AR067701 A1 AR 067701A1 AR P080103246 A ARP080103246 A AR P080103246A AR P080103246 A ARP080103246 A AR P080103246A AR 067701 A1 AR067701 A1 AR 067701A1
Authority
AR
Argentina
Prior art keywords
sodium
inhibitors
glucose
contractor
compositions
Prior art date
Application number
ARP080103246A
Other languages
English (en)
Inventor
Nicole Cathleen Goodwin
Bryce Alden Harrison
Shinya Limura
Ross Mabon
Jie Yan
Matthew Mangzhu Zhang
Wenxue Wu
Qiuling Song
Haiming Zhang
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of AR067701A1 publication Critical patent/AR067701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para sintetizar inhibidores del cotransportador de sodio y glucosa 2 Compuestos utiles para tal fin. Reivindicacion 2: El cocristal de la reivindicacion 1 caracterizado porque el aminoácido aceptable para su uso farmacéutico es L-fenilalanina, L-fenilglicina, o L-arginina.
ARP080103246A 2007-07-26 2008-07-25 Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2 AR067701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95212207P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
AR067701A1 true AR067701A1 (es) 2009-10-21

Family

ID=39877996

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080103246A AR067701A1 (es) 2007-07-26 2008-07-25 Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2
ARP180102213 AR112669A2 (es) 2007-07-26 2018-08-03 Compuestos inhibidores del cotransportador de sodio y glucosa 2 y compuestos útiles para su preparación

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180102213 AR112669A2 (es) 2007-07-26 2018-08-03 Compuestos inhibidores del cotransportador de sodio y glucosa 2 y compuestos útiles para su preparación

Country Status (25)

Country Link
US (2) US8026347B2 (es)
EP (1) EP2183263B1 (es)
JP (2) JP5653213B2 (es)
KR (1) KR101663324B1 (es)
CN (1) CN101801989B (es)
AR (2) AR067701A1 (es)
AT (1) ATE530558T1 (es)
AU (1) AU2008279424B2 (es)
BR (1) BRPI0813840A2 (es)
CA (1) CA2694029C (es)
CL (1) CL2008002169A1 (es)
CO (1) CO6260141A2 (es)
DK (1) DK2183263T3 (es)
EA (1) EA017411B1 (es)
EC (1) ECSP109987A (es)
ES (1) ES2375800T3 (es)
HK (1) HK1143982A1 (es)
IL (1) IL203209A (es)
NZ (1) NZ582536A (es)
PL (1) PL2183263T3 (es)
PT (1) PT2183263E (es)
TW (2) TWI506024B (es)
UA (1) UA107175C2 (es)
WO (1) WO2009014970A1 (es)
ZA (1) ZA201000219B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
AR072511A1 (es) 2008-07-15 2010-09-01 Theracos Inc Derivados deuterados de bencilbenceno y metodos de uso. composicion farmaceutica.
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
NZ591027A (en) 2008-08-28 2012-11-30 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
PT2496583E (pt) 2009-11-02 2015-01-14 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
ES2856888T3 (es) 2009-11-13 2021-09-28 Astrazeneca Ab Formulaciones de tabletas bicapa
CA2780938A1 (en) 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Reduced mass metformin formulations
RS57926B1 (sr) 2009-11-13 2019-01-31 Astrazeneca Ab Formulacije tablete sa trenutnim oslobađanjem
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
MX2013002146A (es) 2010-09-03 2013-04-03 Astrazeneca Uk Ltd Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua.
JP2014504639A (ja) 2011-02-01 2014-02-24 ブリストル−マイヤーズ スクイブ カンパニー アミン化合物を含む医薬製剤
TR201903445T4 (tr) 2011-06-01 2019-03-21 Green Cross Corp Sglt2 i̇nhi̇bi̇törleri̇ olarak yeni̇ di̇feni̇lmetan türevleri̇
CA2837627A1 (en) 2011-06-03 2012-12-06 Boehringer Ingelheim International Gmbh Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
US9200025B2 (en) * 2012-11-20 2015-12-01 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
EP2895490B1 (en) 2013-09-27 2016-10-19 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
ES2969764T3 (es) 2013-12-17 2024-05-22 Boehringer Ingelheim Vetmedica Gmbh Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
SI3485890T1 (sl) 2014-01-23 2023-09-29 Boehringer Ingelheim Vetmedica Gmbh Inhibitorji SGLT2 za zdravljenje presnovnih motenj pri pasjih živalih
EP3721882B1 (en) 2014-04-01 2024-08-28 Boehringer Ingelheim Vetmedica GmbH Treatment of pituitary pars intermedia dysfunction in equine animals
MX2017003716A (es) 2014-09-25 2017-06-30 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de combinacion y/o prevencion de transtorno metabolicos en animales equinos.
EP3466958B1 (en) * 2016-05-25 2020-04-29 Crystal Pharmaceutical (Suzhou) Co., Ltd. New crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof
KR102226465B1 (ko) * 2016-05-28 2021-03-11 하이난 수안주 파마 코포레이션 리미티드 나트륨-글루코스 공수송체 2에 대한 억제제의 결정형
US10640496B2 (en) 2016-06-17 2020-05-05 Daewoong Pharmaceutical Co., Ltd. Method for producing diphenylmethane derivative
KR20190070956A (ko) 2016-10-19 2019-06-21 베링거 인겔하임 인터내셔날 게엠베하 Ssao/vap-1 억제제 및 sglt2 억제제를 포함하는 복합제제 및 이의 용도
CN107540685B (zh) * 2017-09-04 2020-05-05 杭州科巢生物科技有限公司 一种Sotagliflozin的制备方法及其中间体
WO2019201752A1 (en) 2018-04-17 2019-10-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN108675976B (zh) * 2018-05-14 2020-07-14 浙江宏元药业股份有限公司 一种6-卤代葡萄糖碳苷及其制备方法和应用
WO2020036382A1 (ko) 2018-08-13 2020-02-20 주식회사 대웅제약 Sglt 저해제의 합성에 유용한 중간체의 제조
CN110818722B (zh) * 2018-08-14 2022-12-02 苏州鹏旭医药科技有限公司 三种化合物及其制备方法和在合成索格列净中的用途
MX2022006490A (es) 2019-11-28 2022-07-04 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos.
MX2022010090A (es) 2020-02-17 2022-09-02 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos.
MX2024001184A (es) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
MX2024001185A (es) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades renales en mamiferos no humanos.
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
WO2024184293A1 (en) 2023-03-06 2024-09-12 Boehringer Ingelheim Vetmedica Gmbh Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
CZ20023023A3 (cs) 2000-03-17 2003-04-16 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxybenzylbenzenové deriváty, léčivé směsi obsahující tyto látky a meziprodukty pro přípravu derivátů
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
WO2002044192A1 (fr) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
DK1385856T3 (da) 2001-04-11 2006-05-15 Bristol Myers Squibb Co Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
US6562791B1 (en) 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
KR20050005442A (ko) * 2002-04-12 2005-01-13 아칠리온 파르마세우티칼스 인코포레이티드 β-Ｌ-플루오로-2',3'-디데히드로사이티딘(β-Ｌ-ＦＤ4Ｃ)의합성 방법
EP1541578A1 (en) 2002-08-09 2005-06-15 Taisho Pharmaceutical Co., Ltd Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides
KR20050090437A (ko) * 2003-01-03 2005-09-13 브리스톨-마이어스 스큅 컴퍼니 Ｃ-아릴 글루코시드 ｓｇｌｔ２ 억제제의 제조 방법
US7368475B2 (en) * 2003-03-12 2008-05-06 Kemin Pharma Bvba Furanose-type bicyclic carbohydrates with biological activity
US7202350B2 (en) 2003-03-14 2007-04-10 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
WO2006018150A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JP5264183B2 (ja) 2005-02-23 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008044268A1 (fr) * 2006-10-05 2008-04-17 Panasonic Corporation Appareil et procédé de transmission
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法

Also Published As

Publication number Publication date
HK1143982A1 (zh) 2011-01-21
EP2183263B1 (en) 2011-10-26
US8293878B2 (en) 2012-10-23
PL2183263T3 (pl) 2012-03-30
NZ582536A (en) 2012-01-12
CN101801989A (zh) 2010-08-11
PT2183263E (pt) 2012-01-11
CO6260141A2 (es) 2011-03-22
CA2694029A1 (en) 2009-01-29
TW200914434A (en) 2009-04-01
BRPI0813840A2 (pt) 2017-06-06
EA017411B1 (ru) 2012-12-28
IL203209A (en) 2014-02-27
UA107175C2 (uk) 2014-12-10
CN101801989B (zh) 2015-11-25
JP5764174B2 (ja) 2015-08-12
KR20100040869A (ko) 2010-04-21
DK2183263T3 (da) 2012-01-30
JP2014001230A (ja) 2014-01-09
CA2694029C (en) 2016-10-04
AR112669A2 (es) 2019-11-27
TWI419886B (zh) 2013-12-21
KR101663324B1 (ko) 2016-10-06
ECSP109987A (es) 2010-03-31
ES2375800T3 (es) 2012-03-06
CL2008002169A1 (es) 2009-03-20
US8026347B2 (en) 2011-09-27
EA201070186A1 (ru) 2010-08-30
AU2008279424A1 (en) 2009-01-29
WO2009014970A1 (en) 2009-01-29
AU2008279424B2 (en) 2013-06-13
JP5653213B2 (ja) 2015-01-14
US20120095197A1 (en) 2012-04-19
US20090030198A1 (en) 2009-01-29
ZA201000219B (en) 2011-03-30
EP2183263A1 (en) 2010-05-12
JP2010534661A (ja) 2010-11-11
TWI506024B (zh) 2015-11-01
TW201350473A (zh) 2013-12-16
ATE530558T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
AR067701A1 (es) Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2
EA202092001A1 (ru) Соединения для лечения болезни гентингтона
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
CL2007003187A1 (es) Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
GT200600346A (es) Nueva fórmula cristalina v de la agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen
CU20060038A7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
CU20060039A7 (es) Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
CU20060037A7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
EA200970156A1 (ru) Пиридизиноновые производные
EA201071291A3 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
ECSP088800A (es) Formulaciones de inhibidores de DPP IV
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
ECSP11010878A (es) Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv.
EA200702072A1 (ru) Фенилсодержащие n-ацильные производные аминов и аминокислот, способ их получения, фармацевтическая композиция и их применение
BR112012013431A2 (pt) composto, composição farmacêutica e seu uso
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
EA201071019A1 (ru) Кристаллические формы производных фениламинопиримидина
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
UY35275A (es) Derivados de aminopirazina
AR069508A1 (es) Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento
EA200702375A1 (ru) Производные мочевины, способы их получения и применения

Legal Events

Date Code Title Description
FG Grant, registration